Industry News

Led by Genentech's former CSO, Xaira is betting on the application of computational methods to drug design

The radioligand therapy is the first FDA approved treatment specifically for children with gastroenteropancreatic neuroendocrine tumors

Anktiva is the first IL-15 superagonist approved for non-muscle invasive bladder cancer

Facing exploding demand for its weight loss and diabetes drugs, Lilly grabs up a Wisconsin facility

Incyte will pick up two potential first-in-class oral MRGPR antagonists in a deal worth $750 million

The pact grants Ipsen the option to acquire the rights to two candidates pursued under the collaboration

As part of the $380 million deal, Cellares will tech-transfer BMS CAR T-cell therapies onto its fully automated manufacturing platform

Alecensa is now the first and only ALK inhibitor approved for people with ALK-positive early-stage NSCLC following tumor resection

The NaV1.8 inhibitor also nabbed Breakthrough Therapy designation for diabetic peripheral neuropathy pain

The drugmaker shared positive late-stage trial results for its D1/D5 receptor in Parkinson’s disease

The oncology biotech could receive $1.2 billion in milestone payments and royalties on future sales

The drugmaker shared that the trials demonstrated a reduction of up to 63% in the apnea-hypopnea index

Gepotidacin, a potential first-in-class oral antibiotic, is already armed with two positive trials in UTIs

In a phase 3 trial, Columvi plus chemo improved survival rates for patients with relapsed or refractory diffuse large B-cell lymphoma

Fabhalta heads towards another indication with a phase 3 win in rare kidney disease

The UK-based biotech received notice that the 2021 deal will be terminated in 180 days

The review began in July 2023, after two patients in Iceland reported adverse events

The cell culture facility expansion will add large-scale production capacity as well as generate an additional 680 jobs by 2031

The judge said Lilly was attempting to use state laws to enforce federal regulations, which is the responsibility of the FDA

Key to the deal is Alpine’s lead molecule, a dual BAFF/APRIL antagonist in phase 3 trials for kidney disease

The deal, which could reach $1.01 billion, gives Novartis access to a potential first-in-class prostate cancer treatment

The five-year deal aims to improve Novo's drug production and advance scalable manufacturing tech

Novartis plans to cut up to 680 jobs in its drug development unit

After withdrawing the BLA for its ALS candidate, BrainStorm will launch a phase 3b trial this year

Abceutics focuses on payload-binding selectivity enhancers

The recent approval makes Enhertu the first tumor-agnostic HER2-directed therapy

The drugmaker shares promising interim results regarding KarXT's long-term efficacy

In a play to better its cardio health offerings, J&J will pick up a medical device maker active in CAD and PAD

The potential $1.4 billion deal gives Merck KGaA access to Caris' proprietary technologies to develop novel cancer ADCs

A decade after its European launch, Zevtera is now approved for three indications in the U.S.